Health improvement is a key indicator of the state of advancement of a society. Through our research & development efforts, Cephalon contributes to the never ending challenges that sickness and disease pose to our healthcare system. We thrive to provide affordable medicines that make a difference.
Finding new therapeutic solutions for unmet medical needs inspires us as a company. In the mid-1990’s, Cephalon began its operations in Europe by treating disabling excessive daytime sleepiness associated with narcolepsy, which until that time had been inadequately addressed. Today, Cephalon is bringing its innovative perspective to areas such as breakthrough cancer pain, metastatic breast cancer and severe types of leukaemias.
Innovation and services for patients and healtcare professionals are a day-to-day commitment for all employees at Cephalon.
Through the recent acquisition of the Swiss generic Company Mepha, Cephalon provides 150 products and is now able to respond to various needs in the Specialty Pharma and the Generics areas. Providing access to innovation at a cost affordable for the payers is also an important objective to be achieved (25/05/10).
Alain Aragues
Executive Vice President
& President Cephalon Europe
Chairman of the Management Board
of Mepha GmbH